Acne vulgaris Market Growing Demand for New Innovative Products and Treatments

According to Precision Business Insights (PBI), the latest report, the acne vulgaris market is expected to be worth USD 9.2 million in 2022, growing at a 5.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global acne vulgaris market includes the rising prevalence of acne among teenagers & young adults, approval and launch of new drugs & therapies, increasing number of available treatment options, and increasing awareness for acne products.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/acne-vulgaris-market/

Product Segment to Dominate the Acne vulgaris Market:
The global acne vulgaris market is segmented into masks, creams & lotions, cleansers & toners, and others. The creams & lotions segment registered for the maximum acne significant market share in 2021 due to the high demand for beauty products for acne and the growing population suffering from acne vulgaris. Facewash, moisturizer, gel, and serum market is also proliferating with the increasing awareness regarding acne treatment. The other segment is also expected to grow rapidly over the forecast period. Serums became very popular nowadays like salicylic acid, glycolic acid, and niacinamide due to their effectiveness for acne.

Asia Pacific Acne vulgaris Market:
The Asia Pacific market registered the highest CAGR in 2021 in the global acne vulgaris market over the forecast period. It is projected to grow at a considerable CAGR in the coming years. The Asia Pacific market is expanding due to the region's fast-paced lifestyle and growing demand for acne products and treatments. Global key players like Galderma S.A., Pfizer, Allergan, Botanix pharmaceuticals, Sun Pharmaceutical industry, and GlaxoSmithKline are increasing their investment in the research and development sector to invent new innovative and more effective drugs or treatments for acne vulgaris. In addition, North America held a substantial market share in the global acne vulgaris market due to recurring investment & innovative product launches by key global pharmaceutical companies in this region.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The global acne vulgaris market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance, In Aug 2022, Alembic Pharmaceutical announced that its subsidiary company Aleor Dermaceuticals received USFDA approval for its ANDA for Adapalene and Benzoyl peroxide topical gel. In July 2022, Sun Pharmaceutical Industries announced that it has expanded the scope of its partnership with Cassiopea regarding a medication WINLEVI (clascoterone) cream 1% to treat acne.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=58550

The acne vulgaris market is segmented based on therapeutic class, product, formulations, acne type, distribution channel, and geography.
Based on the therapeutic class, the market is segmented into the following:
• Retinoid
• Antibiotic
• Salicylic Acid
• Benzoyl Peroxide
• Others

Based on the product, the market is segmented into the following:
• Mask
• Creams & Lotions
• Cleansers & Toners
• Others

Based on the formulation, the market is segmented into the following:
• Topical Medication
• Oral Medication

Based on the Acne type, the market is segmented into the following:
• Non-inflammatory acne
• Inflammatory acne

Based on the distribution channel, the market is segmented into the following:
• Retail Drug Store
• Hospital Pharmacies
• E-Commerce

Request Methodology: https://precisionbusinessinsights.com/request-methodology?product_id=58550

Key players' profiles in the acne vulgaris market report are Galderma S.A., Pfizer, Allergan, Botanix pharmaceuticals, Sun Pharmaceutical industry, GlaxoSmithKline, Alembic Pharmaceuticals, Almirall, S.A, Johnson & Johnson, Bausch Health Companies, Teva Pharmaceutical Industries Ltd., and Candela Medical.

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.